Credit: Walt Mills/Penn State
“In our lab, we have been working with citrate for over a decade,” said Jian Yang, professor of biomedical engineering, Penn State. “We knew that in the human body, 90 percent of organic citrate is located in skeletal tissue. But no one had really tried to use citrate as a building block to make bone biomaterials. Our new paper tries to understand how citrate helps in bone healing and uses the understanding to guide the design of new biomimetic biomaterials for better bone repair.”
Most bone regeneration in a hospital setting is done through the autograft, taking bone from another part of the patient’s body and grafting it to the wound. This is not a sustainable method, especially in the case of large wounds or bone tissue removed during cancer treatment. Synthetic biomaterials would be a welcome replacement and many labs are working on developing them. But the current synthetic materials cause significant inflammation and the bone healing rate is slow and the healing quality is poor. The body encapsulates the implant with fibrotic tissues that keep the implant from integrating with surrounding bone. With Yang’s material, they do not see encapsulation and the chronic inflammation is minimal.
Chuying Ma, a Ph.D. student in Yang’s lab, is lead author on a paper published in the Proceedings of the National Academy of Sciences (PNAS). Ma was given the problem of uncovering the poorly known mechanism underlying the body’s use of citrate to regenerate bone. She found that the stem cell membrane has a transporter that is used to transport citrate into the cell to elevate the cellular energy level. When the bone stem cells differentiate to make new bone cells, they require more energy as support for active bone formation. The timing and dosage of citrate supply to stem cells are also critical. Yang and Ma coined the newly identified citrate effect on stem cell differentiation as “metabonegenic regulation” in the paper.
The team also identified a second factor involved in energy production, an amino acid called phosphoserine. With their new understanding of the mechanism for bone regrowth, they developed a biomaterial incorporating both citrate and phosphoserine and tested it on rat models. “Using our new material, we see the early deposition of new bone at one month,” Ma said. “This is much earlier than the biomaterials widely used in FDA-approved devices. In this study we tested two models, the femoral condyle bone and the cranial bone defects. In both animal models we see the new biomaterial is better than the commercial materials in inducing early bone formation and also promoting bone maturation.”
Yang added, “To me, this is an important finding. Citrate is now recognized as a central linker between stem cell metabolism and differentiation. We are uncovering the mechanism whereby citrate influences stem cell activity, not only in bone, but by implication extending to other types of cells and tissues. For instance, there is a high concentration of citrate in the cerebrospinal fluid surrounding the brain. People can now use this understanding to start looking at citrate as a metabolism regulator to further regulate stem cells for other types of tissues and organs throughout the body.”
Source: Penn State Materials Research Institute